drugset / Trial / NCT04891185

Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

NCT04891185

Phase 2 Terminated 14 enrolled Universitaire Ziekenhuizen KU Leuven
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Visualise peritoneal lesions of epithelial ovarian cancer (EOC) in both primary and interval debulking surgery by using intravascular indocyanine green (ICG) and near-infrared (NIR) light. This Trial wants to investigate whether ICG can increase the visibility of peritoneal lesions and can differentiate between peritoneal implants and fibrosis.

Timeline

Start
2021-10-01
Primary completion
2023-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.25 mg/kg Intravenous

Indications